How about "The effect of intraoperative cell salvage on allogeneic blood transfusion for patients with placenta accreta"?: An observational study.

Intraoperative cell salvage (IOCS) for high-risk obstetric hemorrhage is now endorsed by a number of obstetric organizations. Most previous studies have focused on the safety of IOCS from case series and small controlled studies. Here, we describe the effect of IOCS on rates of allogeneic blood transfusion (ABT) under different degrees of bleeding during cesarean section in women with placenta accreta, which has seldom been reported in the literature.We conducted a retrospective analysis on the introduction of routine application of IOCS for the management of hemorrhage during cesarean section in women with placenta accreta. We identified 115 women, with prenatally diagnosed placenta accreta/increta/percreta before this change in practice, who served as controls, and 108 women who had IOCS applied during cesarean section.Compared with the control treatment, IOCS was significantly associated with a lower incidence of ABT (odds ratio, 0.179; 95% confidence interval, 0.098-0.328). Among the women with ≤3000 mL of bleeding, ABT was avoided in 80 (93.0%) of the 86 patients in the IOCS group, while 49 (50.0%) of the 98 controls required ABT. For women with an estimated blood loss >3000 mL, the reinfused IOCS blood may have helped prevent the need for ABT in 6 (28.6%) of the 21 patients, while all of the 17 controls required ABT. Subgroup analysis of coagulation function and the need for coagulation components showed no significant difference between the 2 groups (P > .05). Compared with the control treatment, IOCS was associated with a lower intraoperative volume of crystalloid (P < .01) and colloid infusion (P < .01) and a shorter length of postoperative hospital stay (P < .01) in patients with placenta accreta. In addition, there were no complications or adverse reactions in patients with placenta accreta who underwent IOCS.IOCS helped reduce the need for ABT and fluid transfusion in patients with placenta accreta and may be safe for use in obstetrics.